On August 29, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 2019 Wells Fargo Global Healthcare Conference on Wednesday, September 4, 2019 at 11:25 a.m. ET (Press release, MEI Pharma, AUG 29, 2019, View Source [SID1234539132]). The conference will take place September 4‐5, in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

On August 29, 2019 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that Derrick Li, Head of Strategy for the Company, will present at Baird’s 2019 Global Healthcare Conference to be held at the InterContinental New York Barclay in New York, NY on Thursday, September 5, 2019 at 9:40am ET (Press release, Cellular Biomedicine Group, AUG 29, 2019, View Source [SID1234539131]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

For more information about the conference, or to schedule a one-on-one meeting with CBMG management, please contact KCSA Strategic Communications at [email protected], your Baird representative directly, or send an email to [email protected].

On August 29, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that it will participate in two upcoming investor conferences (Press release, CryoLife, AUG 29, 2019, View Source [SID1234539130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CryoLife’s management will be presenting at the Morgan Stanley 17th Annual Healthcare Conference in New York, New York on Wednesday, September 11, 2019 at 11:40 a.m. ET and will feature an overview of the company by Pat Mackin, Chairman, President and Chief Executive Officer. The live webcast can be accessed through CryoLife’s website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same website.

CryoLife’s management will also be participating in investor meetings at the Lake Street 3rd Annual B.I.G. Conference in New York, New York on Thursday, September 12, 2019. Due to the format of this event no webcast will be available.

On August 29, 2019 Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that management will participate in the following upcoming investor conferences in September (Press release, Eiger Biopharmaceuticals, AUG 29, 2019, View Source [SID1234539129]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird 2019 Global Healthcare Conference at the InterContinental Barclay in New York City. Eiger will present a corporate update with a live webcast on September 4, 9:05-9:35 PM ET. Eiger will host one-on-one meetings.
CITI 14th Annual Biotech Conference at the Four Seasons Hotel in Boston on September 5. Eiger will host one-on-one meetings.
H.C. Wainwright Global Investment Conference at the Lotte New York Hotel in New York City. Eiger will present a corporate update with a live webcast on September 10, 3:00-3:25 PM ET. Eiger will host one-on-one meetings.
Ladenburg Thalmann 2019 Healthcare Conference at Sofitel Hotel in New York City. Eiger will present a corporate update with a live webcast on September 24, 12:00-12:25 PM ET. Eiger will host one-on-one meetings.
The live webcast of the Baird, H.C. Wainwright, and Ladenburg presentations will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the live event.

On August 29, 2019 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2019 (Press release, Regulus, AUG 29, 2019, View Source [SID1234539128]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!